Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Accumulation is high here. Nice to see.
Nice to see a voice of reason here. Thanks for the post!
Great! Get a hold of the company and volunteer your services. I'm sure they'd be glad to get some help.
The Preferred have 1000:1 voting rights but only convert to Common at a 1:1.
He sells these, he loses control of the shell. Sounds like, and Really is are two different things in this case.
You found that fake PR first, you may have uploaded it.
Little by little gettin back to the recent highs! We break them and we get an even more bullish chart!
Personally I would like to see MM's dissolved and we go back to On Demand trading. Why should an "authority" figure such as a Market Maker prevent people from buying a stock higher when they do NOTHING to prevent it from being sold off?
This whole notion to make an "orderly" market is such junk. They buy low, sell high, and only prevent stocks from going up too fast.
/rant
I see GREEN is your favourite colour! We do appreciate that!
Decent day.... no major selling, 2950 buy on ask at the end. So far so good!
Once we see something more concrete on the UMK trials, I think we'll be golden here.
I hope Stervc's explaination of why we're happy makes sense. When I first started with buying EXTO back in Jan/Feb of 2011 the float was 479,000,000.
For it to go up only 1.4m shares since then is fantastic. That means that there were not many restricted shares passed out during the last year AND they didn't come into the float!
1.4m at the current .0088 is $12320. Twelve thousand bucks. Anyone who calls that "dumping and dilution" IMO is insane.
Feel free to wait for a lower entry price if you'd like. That choice is yours. Hope that you're not upset if it never arrives.
Problem there missy is that these are Restricted shares. He can not sell them, and if he was to transfer them to anyone else, they would STILL carry a 1 year restriction.
That is included in the form 4. You did read it right?
Yet. I'm sure we'll hear more.
Thanks for the good wishes! We appreciate your support!
*Kisses*
I think you have ideal timing. They're still cheap here, but are slowly drying up.
Next leg up should be a good run.
Ohh are you tryin to get us KILLED???? haha
The company is working on getting the CE removed, a meeting with the new corporate attorney happened on Monday, and we expect that they will become fully reporting within the next few days / weeks.
By the way, sorry for all the fun here at your expense. We've been in this stock for months, and the CE has been beaten over our heads lately.
This board is very very polarized. Most of us believe that something will happen positively soon, while a very vocal minority believe that the company will fall flat on its arse.
Personally, I'm a staunch supporter and sometimes tend to get a bit excessive with my support. Thats why I don't post here much anymore, I do not need to feed the fire and annoy the admin crew. They have way too much work to do to be stuck removing my posts cause I screwed up ;)
Anyways, do yourself a favour, make a few calls, email the company, do what you need to during your search for the truth. IMO, taking EVERYTHING with a grain salt from this board would be wise.
Stervc, one of the assistant Mods has done some wonderful DD here. Search his posts, and you'll get a no nonsense initiation to what COULD happen here very soon.
Good luck to you, hope to see you as one of the EXTO gang. (On the positive side that is)
No PAINTJOB TODAY EITHER. Lots of ask smackage at the end of the day.
Me Like-um!
Lol... eod "Paint" she says.
Trade # 22 Time 15:59:33 BUY 2500 shares @ 0.54
Trade # 23 Time 15:59:34 BUY 2500 shares @ 0.54
BUY volume 43,300
SELL volume 22,500
BUY transactions 18
SELL transactions 5
Someone is keeping this down INTENTIONALLY. We shall see how they like the next month here. I bet they get their shorts scorched.
TDAmeritrade allows trading for EXTO also. Their Trade Architect is pretty good too, allows for customizable screens and has penny stock L2 for free.
Sweet! Glad they're in strong hands. Hopefully we get some news out of them ASAP. Sure would be nice to see progress on the Clinical Trials and on the Proteoderm.
"Probably" differs from "Possibly" due to the degree of certainty. When I say PROBABLY I am pretty guaranteed of it being true.
This is why they probably went this route so they can have other associates purchase on their behalf and by the time its reported, the stock price has already 10-bagged.
Thats not exactly legal unless fully disclosed. Any purchases by officers or affiliates of the company have to be disclosed (within 3 days IIRC) and we'd know if that was the case.
Besides, their shares would automatically be restricted for the duration of their tenure as an officer of the company, limited to 1% of their total being sold every 90 days, also needing disclosure.
Once their tenure is over, this restriction still lasts for 90 additional days, at which time they are able to sell as they want.
They would be "smarter" simply taking their shares in restricted form as "payment" for services rendered, assuming they plan on staying with the company for 1 year.
Audited financials can take forever, and from what I gather there is no need to have audited at this time. Hope they just put in the very basics with regards to their divisions and git er done!
I think someone is playing a shorting game here... wonder who? They'll be sorry tho.
Another strong volume day. Someone has the idea that they can hold the PPS down, but little do they know :)
Intellectual Properties and Patent Applications.
Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
The Development of Identification Biomarkers
A biomarker is a substance used as an indicator of a biological state which refers to the complete range of genes found in biological structure and processes of the living body, including the nervous system, the endocrine system, and our senses of sight, hearing, taste, smell, and touch. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention) cell derivatives, and cellular proteins.
Expansion Technology
Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.
Cryopreservation
Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.
Anti-Inflammatory
Proteonomix's StromaCel™ cellular materials has given some indications as a general anti-inflammatory. We are looking for partners wishing to explore this indication for conditions other than myocardial infarction.
Proteonomix, Inc is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives with an initial focus on diabetes and cardiac diseases.
Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These diseases include, but are not limited to, cancer, heart disease, diabetes, and autoimmune conditions. Stem cell therapy provides much promise for the treatment of diseases previously regarded as incurable.
Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
Expansion Technology:
Proteonomix is developing a unique growth medium that allows expansion far beyond the traditional 10:1 achieved in conventional methods before cellular replication errors make it nonviable. This technology is of benefit to any treatment or process that might be improved by drastically increased concentrations or numbers of cells.
Cryopreservation:
Proteonomix is developing an innovative cryopreservation technique resulting in substantial reduction in lost cells during the freezing and thawing process. This technology is of benefit where it is advantageous to store cellular material for later use, to maintain stock, or to perform long distance transportation.
Anti-Inflammatory:
Proteonomix's StromaCel™ cellular materials has given some indications as a general anti-inflammatory. We are looking for partners wishing to explore this indication for conditions other than myocardial infarction.
We recognize the impact on society that the scarcity of transplant grade umbilical cord blood stem cells imposes; unmet transplantation increases morbidity and mortality. Your company intends to capitalize on this need by creating new stem cell expansion and cryopreservation techniques.
Proteoderm, Inc has developed a line of anti-aging skin care cosmetics based on stem cell derivatives.
Proteoderm is the first company to use a matrix of proteins originally derived from non-embryonic stem cells, Matrix NC-138, to harness the anti-aging potential of stem cells in cosmeceutical products. Proteoderm does not use enzymes, collagen or growth factors which are the ingredients of other anti-aging cosmeceuticals and Proteoderm does not utilize embryonic stem cells as a source for its anti-aging skin care products.
Proteoderm’s Product Line - Matrix NC-138
Proteoderm’s anti-aging skin care system was developed from the research labs of Proteonomix, Inc.. Scientifically studied, and formulated, Proteoderm, Inc. brings lab grade products and services to you. The Matrix NC-138 line of skin care products includes a cleanser, exfoliator, day cream, night cream, and under eye serum. All skin care products can be purchased in an anti-aging kit.
Proteonomix, Inc
Proteoderm, Inc is a wholly-owned subsidiary of Proteonomix, Inc., formally National Stem Cell, Inc..
Proteonomix, Inc. (PROT), www.Proteonomix.com, is a biotechnology company is dedicated to the development of therapeutics based on the use of human cells and their derivatives. Headquartered in Mountainside, New Jersey, Proteonomix has been working for almost a decade with leading scientists and universities, researching the potentials and therapeutics of stem cells to treat a broad array of diseases.
Part 2: Extracted from the White Paper "Secreted Matrix™ and Matrix NC-138™" by Michael Cohen
Function:
Proteins are important signal transducing molecules in cells. In fact, diseases such as diabetes and certain forms of cancer, among other pathologies, are thought to arise due to derangement of protein signaling.
Types of protein signaling:
Protein can refer to two distinct families of proteins. Heterotrimeric proteins sometimes referred to as the large proteins that are activated by specific proteincoupled receptors. There are also small proteins (20-25kDa).
Heterotrimeric proteins:
Heterotrimeric proteins share a common mode of action, i.e., activation in response to a conformation change in the protein-coupled receptor and dissociation in order to activate further proteins in the signal transduction pathway. However, the specific mechanism differs between different types of proteins.
Activation:
When a ligand activates the protein-coupled receptor, it induces a conformation change in the receptor (a change in shape) that allows the receptor to function. In the traditional view of heterotrimeric protein activation, it can then activate different signaling cascades (or second messenger pathways) and effector proteins.
Termination:
The activated protein receptor will eventually hydrolyze and disassociate from the heterotrimeric activating protein.
Matrix NC-138™:
Bioactive proteins have been defined as specific protein that have a positive impact on body functions or conditions and may ultimately influence health. The activity of these biofunctional proteins contained in the isolated Secreted Matrix™ is based on their inherent amino acid composition and sequence. The length of active proteins may vary from two to more than 100 amino acids and are known to have multifunctional properties. Matrix NC-138™ is a further isolation of Secreted Matrix™ for the specific bioactive proteins whose action on skin is to enhance activities through stimulation of collagen production, glandular production or reduction of wrinkles. This is the efficacy of the Proteoderm Matrix NC-138™ product as demonstrated in vitro and in vivo at University Laboratory studies. Our University Laboratory in vivo studies demonstrated high level of efficacy of Matrix NC-138™.These laboratory studies correlate with our on going large scale clinical trials.
Proteoderm’s expertise in biotechnology led to the development of cutting edge anti-aging skin care products. The Proteoderm system works to revitalize and rejuvenate your own cells to help drastically reverse the effects of aging!
Proteoderm has used its expertise in
protein technology to develop a unique,natural matrix of proteins called Matrix™ NC-138 for use in anti-aging skin products. Matrix™ NC-138 acts on the skin to enhance activities that reduce wrinkles.
Proteonomix, Inc.
The Company for Life's Journey.
Our mission is to focus upon the development of therapies based upon the use of human stem cells and their derivatives, particularly in the areas of diabetes and cardiac diseases. We primarily employ bone marrow, pancreatic, and umbilical cord blood derived cells in a process of identification, separation, expansion and delivery towards treatment of diseases previously considered incurable. It is our further goal to deliver these therapies to the widest possible spectrum of patients both geographically and economically in the minimum time.
Great day. Excellent volume, cleared out a bunch more shares in the .80s lookin for $1 in the next week!
BIG chunk of stock cleaned out here today. Love to see that. The next set of buying pressure will take us back up where we should be.
Good job today!
Yup the next few weeks will be even better I'd bet.
Strong volume and PPS increase today! The attempted shake wasnt very successful huh.
Glad we all got to pick up some more cheapies before this steamrolls north.